Neurocrine Biosciences, Inc. (NBIX) – Buzz Stock of the Day

We first covered Neurocrine Biosciences, Inc. (Nasdaq: NBIX) in late May 2010, when the stock was trading at $3.40 a share. About a week after our post, shares of NBIX climbed to a high of $5.20 a share. Neurocrine rallied again on Thursday, climbing almost 8 percent to a 52-week high of $5.79 a share in morning trading after the company announced a development deal with privately held German drug maker, Boehringer Ingelheim.

[–quote–]

The two companies will work together to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications . Neurocrine will get a $10 million upfront payment and research funding to support discovery efforts. The company is also eligible to receive up to $225 million in milestone payments, according to Neurocrine.

A day before, Neurocrine licensed the worldwide rights to its experimental endometriosis drug to Abbott Laboratories. Under terms of the deal announced Wednesday, Abbott gains worldwide rights to elagolix in exchange for a $50 million upfront payment to Neurocrine. Abbott agreed to pay all future development costs for the drug. Neurocrine is eligible for up to $500 million in future milestone payments as well as royalties based on sales of elagolix if approved.

Tags: biotech, nasdaq, nbix, pharmaceutical stocks, strategic partnerships

This entry was posted on Thursday, June 17th, 2010 at 5:46 pm by admin and is filed under Health Care Stocks, Technology Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.